Nanjing Leads Biolabs Narrows H1 Loss; Shares Gain 2%

MT Newswires Live
2025/09/01

Nanjing Leads Biolabs (HKG:9887) posted a loss attributable to owners of 166.4 million yuan for the first half of 2025, compared with a 180.4 million yuan loss a year earlier, according to an Aug. 29 Hong Kong bourse filing.

Shares of the clinical-stage biotech were up nearly 2% in Monday afternoon trade.

Loss per share was 1.06 yuan, compared with 1.22 yuan in the same period last year.

It reported no nil revenue for the reporting period.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10